Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.

Literature DB >> 2175265

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.

M Maurer¹, V Henn, A Dittrich, A Hofmann.

Abstract

A double-blind study was performed comparing 5 mg delta-9-tetrahydrocannabinol (THC) p.o., 50 mg codeine p.o., and placebo in a patient with spasticity and pain due to spinal cord injury. The three conditions were applied 18 times each in a randomized and balanced order. Delta-9-THC and codeine both had an analgesic effect in comparison with placebo. Only delta-9-THC showed a significant beneficial effect on spasticity. In the dosage of THC used no altered consciousness occurred.

Entities: Chemical Disease Species

Mesh：

Substances：
Dronabinol

Year: 1990 PMID： 2175265 DOI： 10.1007/BF02190083

Source DB: PubMed Journal: Eur Arch Psychiatry Clin Neurosci ISSN： 0940-1334 Impact factor: 5.270

8 in total

1. AN APPROACH TO THE EVALUATION OF DRUG EFFECT DURING PSYCHOTHERAPY: A DOUBLE-BLIND STUDY OF A SINGLE CASE.

Authors: L BELLAK; J B CHASSAN
Journal: J Nerv Ment Dis Date: 1964-07 Impact factor: 2.254

2. Statistical inference and the single case in clinical design.

Authors: J B CHASSAN
Journal: Psychiatry Date: 1960-05 Impact factor: 2.458

3. The perceived effects of marijuana on spinal cord injured males.

Authors: M Dunn; R Davis
Journal: Paraplegia Date: 1974-11

4. Marihuana as a therapeutic agent for muscle spasm or spasticity.

Authors: D J Petro
Journal: Psychosomatics Date: 1980-01 Impact factor: 2.386

5. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

Authors: H M Meinck; P W Schönle; B Conrad
Journal: J Neurol Date: 1989-02 Impact factor: 4.849

6. The analgesic properties of delta-9-tetrahydrocannabinol and codeine.

Authors: R Noyes; S F Brunk; D A Avery; A C Canter
Journal: Clin Pharmacol Ther Date: 1975-07 Impact factor: 6.875

7. Cannabis effect on spasticity in spinal cord injury.

Authors: J Malec; R F Harvey; J J Cayner
Journal: Arch Phys Med Rehabil Date: 1982-03 Impact factor: 3.966

8. Treatment of human spasticity with delta 9-tetrahydrocannabinol.

Authors: D J Petro; C Ellenberger
Journal: J Clin Pharmacol Date: 1981 Aug-Sep Impact factor: 3.126

8 in total

13 in total

Review 1. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

Authors: F A Campbell; M R Tramèr; D Carroll; D J Reynolds; R A Moore; H J McQuay
Journal: BMJ Date: 2001-07-07

2. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

Authors: Weisi Fu; Bradley K Taylor
Journal: Neurosci Lett Date: 2015-04-03 Impact factor: 3.046

3. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.

Authors: Jörg Wissel; Tanja Haydn; Jörg Müller; Christian Brenneis; Thomas Berger; Werner Poewe; Ludwig D Schelosky
Journal: J Neurol Date: 2006-09-20 Impact factor: 4.849

10. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors: J Manzanares; Md Julian; A Carrascosa
Journal: Curr Neuropharmacol Date: 2006-07 Impact factor: 7.363

Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial.

1. AN APPROACH TO THE EVALUATION OF DRUG EFFECT DURING PSYCHOTHERAPY: A DOUBLE-BLIND STUDY OF A SINGLE CASE.

2. Statistical inference and the single case in clinical design.

3. The perceived effects of marijuana on spinal cord injured males.

4. Marihuana as a therapeutic agent for muscle spasm or spasticity.

5. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis.

6. The analgesic properties of delta-9-tetrahydrocannabinol and codeine.

7. Cannabis effect on spasticity in spinal cord injury.

8. Treatment of human spasticity with delta 9-tetrahydrocannabinol.

Review 1. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review.

2. Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.

3. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain : a double-blind placebo-controlled cross-over trial.

Review 4. Role of cannabinoids in the treatment of pain and (painful) spasticity.

Review 5. Pharmacokinetics and pharmacodynamics of cannabinoids.

Review 6. [Therapeutic use of cannabinoids in neurology].

Review 7. Cannabinoid-based medicines for neurological disorders--clinical evidence.

Review 8. Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.

Review 9. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside.

10. Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.